The FDA has categorized this as a Class I recall. However, patients can still use the devices as long as they follow specific instructions provided by the manufacturer.
The greater cardiology community was hopeful ZEUS could open the door for significant improvements in patient care. After the trial failed to deliver on that promise, it's time to consider where things went wrong.
GLP-1 receptor agonists have been associated with a wide range of potential benefits for patients with and without type 2 diabetes. The team behind this new meta-analysis hoped to learn more about how the popular medications may impact a person's risk of new-onset AFib.
A new analysis suggests that these AI-assessed scores could help identify patients at elevated cardiovascular risk even when their coronary calcium levels are low or absent on imaging.
Cardiologist Philippe Généreux spoke to Cardiovascular Business about the highly anticipated PROGRESS trial. "What we learned from this trial is that moderate aortic stenosis should not be seen anymore as a benign entity," he said.
More and more clinicians are using advanced CCTA technologies to diagnose, treat and manage patients with suspected coronary artery disease. An upcoming webinar will include a deep dive into that very topic, highlighting why the modality is such a game-changer for patient care.
Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.
